HCA Health Inc vs McCormick & Company, Incorporated — how do they compare? HCA Health Inc trades at $450.18 (market cap $96.35B), while McCormick & Company, Incorporated trades at $44.88 (market cap $12.39B). The key difference: HCA Health Inc is far larger — about 7.8× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays the higher dividend (4.18%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and McCormick & Company, Incorporated for 67 Days on average.
| HCA | MKC | |
|---|---|---|
Market Cap | $96.35B | $12.39B |
Volume | 1,079,453 | 6,140,872 |
Sector | Health | Consumer Staples |
52-Week High | $545.13 | $71.65 |
52-Week Low | $361.32 | $44.14 |
Typical Hold Time | 76 Days | 67 Days |
Enterprise Value | $146.88B | $17.07B |
Dividend Yield | 0.7% | 4.18% |
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $449.47, up 2.35% with bullish technical indicators and strong fundamental performance. The stock shows consistent earnings beats with Q2 2026 EPS of $7.59 exceeding expectations, while revenue growth continues from $75.6B in 2025 to projected $78.0B in 2026. Analyst consensus remains strongly positive with 63% buy ratings and $461.12 price target, though legal investigations present headwinds.
The outlook remains favorable with solid patient demand and operational efficiency driving growth, though investors should monitor ongoing legal investigations and debt levels. Valuation appears reasonable with P/E of 14.92 and EV/EBITDA of 9.26, while technical support at $440 provides near-term stability.
McCormick (MKC) trades at $44.81, down 0.97% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with EPS of $0.86, driven by margin expansion and the McCormick de Mexico acquisition. Revenue grew 17% in constant currency, and the full-year outlook was reaffirmed. Valuation ratios appear attractive with a P/E of 8.31 and net income margin of 19.39%, while cash flow trends show improvement in 2026.
The outlook is mixed; fundamentals are solid with earnings beats and dividend growth, but technicals and analyst sentiment lean cautious. Upside exists if execution continues, yet risks include integration challenges and macroeconomic pressures. The consensus price target of $53.50 implies potential appreciation, but near-term volatility may persist.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →